Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer
NCT02023021Phase 2Completed
- Sponsor
- Xian-Jun Yu
- Start
- Jan 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Xian-Jun Yu. Primary endpoint: Recurrence-free survival at 1 year. Started Jan 2014; status: completed.
02
Drugs
paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02023021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023021.